from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2xGtT08 on September 27, 2018 at 07:25PM
AstraZeneca CEO Pascal Soriot in recent interviews discussed the companies recent moves as Brexit and EU customs talks continue, as well as his salary compared to his peers, according to a PMLiVE report.
Soriot in interviews with the Times and Sunday Times said the company had boosted its medicine stocks by some 20 percent, and “wasted” about $53 million on labs in Sweden to keep products on the market.
Failure to reach a deal on customs would be “really painful,” the executive said.
“I hope more and more people get worried,” he added.
Soriot also claims to be the lowest-paid CEO in the pharmaceutical industry, and that GlaxoSmithKline’s Emma Walmsley is also underpaid compared with their peers.
To read the full report on PMLiVE, click here.